Posts Tagged ‘JUPITER’

February 17th, 2014

Another Satellite of JUPITER: Lipoprotein(a)

Amit V. Khera discusses his study group’s analysis of lipoprotein(a) concentrations and residual vascular risk among participants in the placebo-controlled JUPITER trial of rosuvastatin.

September 23rd, 2013

HDL-P: The Better Marker of Residual Risk?

CardioExchange Editors interview Samia Mora about her investigative group’s analysis of data from the JUPITER trial, which reveals that HDL-P may be a better marker of residual risk than chemically measured HDL-C or apoA-1.

August 9th, 2012

Reports from JUPITER and Taiwan: Benefits of Statins Outweigh Risk for Diabetes

Two new papers provide further evidence that statin use is associated with an increased risk for diabetes, but both studies also find that the benefits of statins still outweigh the risks. In one report, published in the Lancet, Paul Ridker and colleagues analyze data from the JUPITER trial, which compared rosuvastatin to placebo in a primary-prevention population. Among the 17,603 […]

January 23rd, 2012

Rita Redberg and Roger Blumenthal Clash Over Statins for Primary Prevention in the Wall Street Journal

The debate over whether statins should be used for primary prevention moved to the Wall Street Journal with opposing perspectives from cardiologists Roger Blumenthal and Rita Redberg. Blumenthal argues that “there is a mountain of high-quality scientific evidence” to support the use of statins in people without known heart disease but “demonstrated to be at high risk for […]

July 22nd, 2010

HDL and Residual Risk: A Surprising Finding in JUPITER

CardioExchange welcomes Dr. Paul Ridker to answer questions about his recent paper in the Lancet, which analyzed data from JUPITER and found that HDL may not predict residual risk in patients on high-dose statins who reach very low LDL levels such as those achieved in the treatment group in JUPITER. The findings may surprise some readers, though […]